SARS-CoV-2 variant of concern

Last updated

SARS-CoV-2, the virus that causes COVID-19 Novel Coronavirus SARS-CoV-2.jpg
SARS-CoV-2, the virus that causes COVID-19

The term variant of concern (VOC) for SARS-CoV-2, which causes COVID-19, is a category used for variants of the virus where mutations in their spike protein receptor binding domain (RBD) substantially increase binding affinity (e.g., N501Y) in RBD-hACE2 complex (genetic data), while also being linked to rapid spread in human populations (epidemiological data). [1]

Contents

Before being allocated to this category, an emerging variant may have been labeled a variant of interest (VOI), [2] or in some countries a variant under investigation (VUI). [3] During or after fuller assessment as a variant of concern the variant is typically assigned to a lineage in the Pango nomenclature system [4] and to clades in the Nextstrain [5] and GISAID [6] systems.

During the COVID-19 pandemic, the SARS-CoV-2 virus has been observed to mutate, with certain combinations of specific point mutations proving to be more concerning than others. [7] This was principally for reasons of transmissibility and virulence, and also with regard to the possible emergence of escape mutations.

Criteria

Several national and international health organisations (e.g. Centers for Disease Control and Prevention (CDC) (US), Public Health England (PHE) and the COVID-19 Genomics UK Consortium for the UK, and the Canadian COVID Genomics Network (CanCOGeN)) use some or all of the following criteria to assess variants: [8] [9]

Variants that appear to meet one or more of these criteria may be labeled "variants of interest" or "variants under investigation" ('VUI') pending verification and validation of these properties. Once validated, variants of interest /VUI may be renamed "variants of concern" by monitoring organizations, such as the CDC. [3] [7] [10] A related category is "variant of high consequence", used by the CDC if there is clear evidence that the effectiveness of prevention or intervention measures for a particular variant is substantially reduced. [11]

Classifications by country

World Health Organization

The WHO maintains a list of variants of global concern. [2] On 26 November 2021, the WHO added a fifth variant of concern, the Omicron variant, previously known as B.1.1.529. [12] Omicron joins the Alpha, Beta, Gamma, and Delta variants.[ citation needed ] As of March 2023, these are all considered to be 'previously circulating' variants of concern, and classified Omicron sublineages independently as variants under monitoring (VUMs), VOIs, or VOCs. [13]

Africa

The NICD in South Africa maintains a list of variants and testing facilities locally in collaboration with KRISP. [14] [15]

Europe

As of November 2021, the European Centre for Disease Prevention and Control declared four variants to be 'variants of concern': Beta, Gamma, Delta, and B.1.1.529 (named 'Omicron' after the reference was updated); Mu, Lambda and AY.4.2 were named as Variants of Interest (VOI), while there were 9 'Variants under monitoring'. 25 variants were described as 'de-escalated'. [16]

United Kingdom

As of November 2021, the United Kingdom has fifteen variants on its 'watch list', 4 with 'VOC' status and 11 rated as 'VUI'. Those designated 'VOC' were Alpha, Beta, Gamma, and Delta. In early December 2021, Omicron was added to the VOCs. Among the Variants under investigation is 'VUI-21OCT-01/ A.Y 4.2'. [17]

North America

Canada (via health-infobase.canada.ca) [18] and the United States (via the CDC) [19] also maintain lists of variants of concern. As of early December, Canada was monitoring five variants of concern: Alpha, Beta, Gamma, Delta, and Omicron, while the US was monitoring two: Delta and Omicron. [20]

Related Research Articles

COVID-20, COVID-21 or COVID-22 may refer to:

<span class="mw-page-title-main">SARS-CoV-2 in mink</span>

Both the American mink and the European mink have shown high susceptibility to SARS-CoV-2 since the earliest stages of the COVID-19 pandemic, first in mink farms across Europe, followed by mink farms in the United States. Mortality has been extremely high among mink, with 35–55% of infected adult animals dying from COVID-19 in a study of farmed mink in the U.S. state of Utah.

<span class="mw-page-title-main">SARS-CoV-2 Alpha variant</span> Variant of SARS-CoV-2, the virus that causes COVID-19

The Alpha variant (B.1.1.7) was a SARS-CoV-2 variant of concern. It was estimated to be 40–80% more transmissible than the wild-type SARS-CoV-2. Scientists more widely took note of this variant in early December 2020, when a phylogenetic tree showing viral sequences from Kent, United Kingdom looked unusual.

<span class="mw-page-title-main">SARS-CoV-2 Beta variant</span> Variant of the SARS-CoV-2 virus

The Beta variant, (B.1.351), was a variant of SARS-CoV-2, the virus that causes COVID-19. One of several SARS-CoV-2 variants initially believed to be of particular importance, it was first detected in the Nelson Mandela Bay metropolitan area of the Eastern Cape province of South Africa in October 2020, which was reported by the country's health department on 18 December 2020. Phylogeographic analysis suggests this variant emerged in the Nelson Mandela Bay area in July or August 2020.

<span class="mw-page-title-main">Variants of SARS-CoV-2</span> Notable variants of SARS-CoV-2

Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are viruses that, while similar to the original, have genetic changes that are of enough significance to lead virologists to label them separately. SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Some have been stated, to be of particular importance due to their potential for increased transmissibility, increased virulence, or reduced effectiveness of vaccines against them. These variants contribute to the continuation of the COVID-19 pandemic.

<span class="mw-page-title-main">SARS-CoV-2 Gamma variant</span> Variant of the virus SARS-CoV-2

The Gamma variant (P.1) was one of the variants of SARS-CoV-2, the virus that causes COVID-19. This variant of SARS-CoV-2 has been named lineage P.1 and has 17 amino acid substitutions, ten of which in its spike protein, including these three designated to be of particular concern: N501Y, E484K and K417T. It was first detected by the National Institute of Infectious Diseases (NIID) of Japan, on 6 January 2021 in four people who had arrived in Tokyo having visited Amazonas, Brazil, four days earlier. It was subsequently declared to be in circulation in Brazil. Under the simplified naming scheme proposed by the World Health Organization, P.1 was labeled Gamma variant, and was considered a variant of concern until March 2022, when it was largely displaced by the delta and omicron variants.

<span class="mw-page-title-main">Phylogenetic Assignment of Named Global Outbreak Lineages</span> SARS-CoV-2 lineage nomenclature

The Phylogenetic Assignment of Named Global Outbreak Lineages (PANGOLIN) is a software tool developed by Dr. Áine O'Toole and members of the Andrew Rambaut laboratory, with an associated web application developed by the Centre for Genomic Pathogen Surveillance in South Cambridgeshire. Its purpose is to implement a dynamic nomenclature to classify genetic lineages for SARS-CoV-2, the virus that causes COVID-19. A user with a full genome sequence of a sample of SARS-CoV-2 can use the tool to submit that sequence, which is then compared with other genome sequences, and assigned the most likely lineage. Single or multiple runs are possible, and the tool can return further information regarding the known history of the assigned lineage. Additionally, it interfaces with Microreact, to show a time sequence of the location of reports of sequenced samples of the same lineage. This latter feature draws on publicly available genomes obtained from the COVID-19 Genomics UK Consortium and from those submitted to GISAID. It is named after the pangolin.

<span class="mw-page-title-main">SARS-CoV-2 Iota variant</span> Variant of the SARS-Cov-2 virus first identified in New York City

Iota variant, also known as lineage B.1.526, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. It was first detected in New York City in November 2020. The variant has appeared with two notable mutations: the E484K spike mutation, which may help the virus evade antibodies, and the S477N mutation, which helps the virus bind more tightly to human cells.

<span class="mw-page-title-main">SARS-CoV-2 Delta variant</span> Variant of SARS-CoV-2 detected late 2020

The Delta variant (B.1.617.2) was a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in India on 5 October 2020. The Delta variant was named on 31 May 2021 and had spread to over 179 countries by 22 November 2021. The World Health Organization (WHO) indicated in June 2021 that the Delta variant was becoming the dominant strain globally.

<span class="mw-page-title-main">SARS-CoV-2 Theta variant</span> Variant of the SARS-CoV-2 virus

Theta variant, also known as lineage P.3, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. The variant was first identified in the Philippines on February 18, 2021, when two mutations of concern were detected in Central Visayas. It was detected in Japan on March 12, 2021, when a traveler from the Philippines arrived at Narita International Airport in Tokyo.

<span class="mw-page-title-main">SARS-CoV-2 Kappa variant</span> Type of the virus detected in 2020

Kappa variant is a variant of SARS-CoV-2, the virus that causes COVID-19. It is one of the three sublineages of Pango lineage B.1.617. The SARS-CoV-2 Kappa variant is also known as lineage B.1.617.1 and was first detected in India in December 2020. By the end of March 2021, the Kappa sub-variant accounted for more than half of the sequences being submitted from India. On 1 April 2021, it was designated a Variant Under Investigation (VUI-21APR-01) by Public Health England.

Lineage B.1.617 is a lineage of SARS-CoV-2, the virus that causes COVID-19. It first came to international attention in late March 2021 after the newly established INSACOG performed genome sequencing on positive samples throughout various Indian states. Analysis of samples from Maharashtra had revealed that compared to December 2020, there was an increase in the fraction of samples with the E484Q and L452R mutations. Lineage B.1.617 later came to be dubbed a double mutant by news media.

<span class="mw-page-title-main">SARS-CoV-2 Lambda variant</span> Variant of SARS-CoV-2

The Lambda variant, also known as lineage C.37, is a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in Peru in August 2020. On 14 June 2021, the World Health Organization (WHO) named it Lambda variant and designated it as a variant of interest. It has spread to at least 30 countries around the world and is known to be more resistant to neutralizing antibodies compared to other strains. There is evidence that suggests the Lambda variant is both more infectious and resistant to vaccines than the Alpha and/or Gamma variant.

<span class="mw-page-title-main">SARS-CoV-2 Epsilon variant</span> Variant of the SARS-Cov-2 virus

Epsilon variant, also known as CAL.20C and referring to two PANGO lineages B.1.427 and B.1.429, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. It was first detected in California, USA in July 2020.

<span class="mw-page-title-main">SARS-CoV-2 Zeta variant</span> Variant of the SARS-Cov-2 virus

Zeta variant, also known as lineage P.2, is a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in the state of Rio de Janeiro; it harbors the E484K mutation, but not the N501Y and K417T mutations. It evolved independently in Rio de Janeiro without being directly related to the Gamma variant from Manaus.

<span class="mw-page-title-main">SARS-CoV-2 Eta variant</span> Variant of the SARS-Cov-2 virus

The Eta variant is a variant of SARS-CoV-2, the virus that causes COVID-19. The Eta variant or lineage B.1.525, also called VUI-21FEB-03 by Public Health England (PHE) and formerly known as UK1188, 21D or 20A/S:484K, does not carry the same N501Y mutation found in Alpha, Beta and Gamma, but carries the same E484K-mutation as found in the Gamma, Zeta, and Beta variants, and also carries the same ΔH69/ΔV70 deletion as found in Alpha, N439K variant and Y453F variant.

<span class="mw-page-title-main">SARS-CoV-2 Mu variant</span> Variant of the SARS-CoV-2 virus

The Mu variant, also known as lineage B.1.621 or VUI-21JUL-1, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. It was first detected in Colombia in January 2021 and was designated by the WHO as a variant of interest on August 30, 2021. The WHO said the variant has mutations that indicate a risk of resistance to the current vaccines and stressed that further studies were needed to better understand it. Outbreaks of the Mu variant were reported in South America and Europe. The B.1.621 lineage has a sublineage, labeled B.1.621.1 under the PANGO nomenclature, which has already been detected in more than 20 countries worldwide.

<span class="mw-page-title-main">SARS-CoV-2 Omicron variant</span> Type of the virus first detected in November 2021

Omicron (B.1.1.529) is a variant of SARS-CoV-2 first reported to the World Health Organization (WHO) by the Network for Genomics Surveillance in South Africa on 24 November 2021. It was first detected in Botswana and has spread to become the predominant variant in circulation around the world. Following the original B.1.1.529 variant, several subvariants of Omicron have emerged including: BA.1, BA.2, BA.3, BA.4, and BA.5. Since October 2022, two subvariants of BA.5 called BQ.1 and BQ.1.1 have emerged.

<span class="mw-page-title-main">Timeline of the SARS-CoV-2 Omicron variant</span>

This timeline of the SARS-CoV-2 Omicron variant is a dynamic list, and as such may never satisfy criteria of completeness. Some events may only be fully understood and/or discovered in retrospect.

<span class="mw-page-title-main">SARS-CoV-2 in white-tailed deer</span>

Blood samples gathered by USDA researchers in 2021 showed that 40% of sampled white-tailed deer demonstrated evidence of SARS-CoV-2 antibodies, with the highest percentages in Michigan, at 67%, and Pennsylvania, at 44%. A later study by Penn State University and wildlife officials in Iowa showed that up to 80% of Iowa deer sampled from April 2020 through January 2021 had tested positive for active SARS-CoV-2 infection, rather than solely antibodies from prior infection. This data, confirmed by the National Veterinary Services Laboratory, alerted scientists to the possibility that white-tailed deer had become a natural reservoir for the coronavirus, serving as a potential "variant factory" for eventual retransmission back into humans.

References

  1. Shahhosseini, Nariman; Babuadze, George (Giorgi); Wong, Gary; Kobinger, Gary P. (May 2021). "Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern". Microorganisms. 9 (5): 926. doi: 10.3390/microorganisms9050926 . PMC   8146828 . PMID   33925854.
  2. 1 2 "Tracking SARS-CoV-2 variants". www.who.int. Retrieved 28 November 2021.
  3. 1 2 "Variants: distribution of cases data". GOV.UK. 28 January 2021. At "Differences between a Variant of Concern and Variant Under Investigation". Retrieved 19 February 2021. SARS-CoV-2 variants, if considered to have concerning epidemiological, immunological, or pathogenic properties, are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, month, and number. Following a risk assessment with the relevant expert committee, they may be designated Variant of Concern (VOC)
  4. Rambaut, A.; Holmes, E.C.; O’Toole, Á.; et al. (2020). "A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology". Nature Microbiology. 5 (11): 1403–1407. doi: 10.1038/s41564-020-0770-5 . PMC   7610519 . PMID   32669681. S2CID   220544096.
  5. Bedford, Trevor; Hodcroft, Emma B; Neher, Richard A (6 January 2021). "Updated Nextstrain SARS-CoV-2 clade naming strategy". nextstrain.org/blog. Retrieved 19 January 2021.
  6. "clade tree (from 'Clade and lineage nomenclature')". www.gisaid.org. 4 July 2020. Retrieved 7 January 2021.
  7. 1 2 Griffiths, Emma; Tanner, Jennifer; Knox, Natalie; Hsiao, Will; Van Domselaar, Gary (15 January 2021). "CanCOGeN Interim Recommendations for Naming, Identifying, and Reporting SARS-CoV-2 Variants of Concern" (PDF). CanCOGeN (nccid.ca). Retrieved 25 February 2021.
  8. Lucey, Daniel R. (2 February 2021). "COVID "Mega-variant" and eight criteria for a template to assess all variants". Science Speaks: Global ID News. Retrieved 5 June 2022.
  9. CDC (11 February 2020). "Emerging SARS-CoV-2 Variants". Centers for Disease Control and Prevention. Retrieved 4 January 2021.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  10. "Investigation of SARS-CoV-2 variants of concern in England; Technical briefing 6 (See section: Nomenclature of variants in the UK, P.3)" (PDF). assets.publishing.service.gov.uk. 13 February 2021. Retrieved 27 February 2021.
  11. CDC (11 February 2020). "Cases, Data, and Surveillance". Centers for Disease Control and Prevention. Retrieved 16 March 2021.
  12. "Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern". World Health Organization. Retrieved 28 November 2021.
  13. "Statement on the update of WHO's working definitions and tracking system for SARS-CoV-2 variants of concern and variants of interest". www.who.int. Retrieved 19 April 2024.
  14. "New COVID-19 variant detected in South Africa". NICD. 25 November 2021. Retrieved 29 November 2021.
  15. "Kwazulu-Natal Research Innovation and Sequencing Platform". www.krisp.org.za. Retrieved 29 November 2021.
  16. "SARS-CoV-2 variants of concern". www.ecdc.europa.eu. 26 November 2021. Retrieved 27 November 2021.
  17. "Variants of concern or under investigation: data up to 24 November 2021". www.gov.uk. 26 November 2021. Retrieved 27 November 2021.
  18. Canada, Public Health Agency of (19 April 2020). "COVID-19 daily epidemiology update: Summary". aem. Retrieved 13 May 2021.
  19. "SARS-CoV-2 Variant Classifications and Definitions". Centers for Disease Control and Prevention. 11 February 2020. Retrieved 30 April 2021.
  20. "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. 11 February 2020. Retrieved 7 December 2021.